What is the price target for NEO stock?
18 analysts have analysed NEO and the average price target is 14.22 USD. This implies a price increase of 79.13% is expected in the next year compared to the current price of 7.94.
NEOGENOMICS INC (NEO) Forecast, Price Target & Analyst Ratings
NASDAQ:NEO • US64049M2098
Current stock price
7.94 USD
-0.28 (-3.41%)
At close:
7.94 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEOGENOMICS INC (NEO).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 27, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.01
- Revenue Estimate
- 186.38M
Price Target Details & History
Consensus Price Target and Range
Mean target
$14.22
Upside
+ 79.13%
From current price of $7.94 to mean target of $14.22, Based on 18 analyst forecasts
Low
$7.07
Median
$15.30
High
$17.85
Price Target Revisions
1 Month
0.80%
3 Months
9.13%
Price Target Summary
18 Wall Street analysts provided a forecast for the next 12 months for NEO. The average price target is 14.22 USD. This implies a price increase of 79.13% is expected in the next year compared to the current price of 7.94.
The average price target has been revised upward by 9.13% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
72.22%
NEO was analyzed by 18 analysts. The buy percentage consensus is at 72. So analysts seem to be have mildly positive about NEO.
In the previous month the buy percentage consensus was at a similar level.
NEO was analyzed by 18 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-24 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-17 | Needham | Maintains | Buy -> Buy |
| 2026-01-12 | Needham | Reiterate | Buy -> Buy |
| 2025-09-12 | TD Cowen | Maintains | Buy -> Buy |
| 2025-09-02 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2025-08-29 | Needham | Maintains | Buy -> Buy |
| 2025-08-04 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-07-30 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-29 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-07-29 | Needham | Maintains | Buy -> Buy |
| 2025-05-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-01 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-30 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-04-30 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-29 | Needham | Maintains | Buy -> Buy |
| 2025-04-17 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-02-26 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-19 | Needham | Maintains | Buy -> Buy |
| 2025-02-19 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-01-28 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-01-16 | Benchmark | Reiterate | Hold -> Hold |
| 2025-01-15 | Needham | Reiterate | Buy -> Buy |
| 2025-01-13 | Benchmark | Downgrade | Buy -> Hold |
| 2025-01-10 | Needham | Reiterate | Buy -> Buy |
| 2024-12-13 | B of A Securities | Maintains | Neutral -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 27, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.01
- Revenue Estimate
- 186.38M
- Revenue Q2Q
- 10.92%
- EPS Q2Q
- N/A
- Number of Analysts
- 15
Next Earnings Revisions
Revenue (1 Month)
0.02%
Revenue (3 Months)
-1.57%
EPS (1 Month)
-16.46%
EPS (3 Months)
-26.90%
Next Earnings Summary
NEO is expected to report earnings on 4/27/2026. The consensus EPS estimate for the next earnings is 0.01 USD and the consensus revenue estimate is 186.38M USD.
The next earnings revenue estimate has been revised downward by 1.57% in the past 3 months.
Full Analyst Estimates 2026 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 591.643M 16.08% | 660.566M 11.65% | 727.332M 10.11% | 804.64M 10.63% | 882.96M 9.73% | 963.4M 9.11% | 1.035B 7.43% | 1.118B 8.02% | |
| EBITDA YoY % growth | -24.065M 71.24% | -12.901M 46.39% | -20.304M -57.38% | 55.796M 374.80% | 76.886M 37.80% | 100.25M 30.39% | 140.29M 39.94% | N/A | |
| EBIT YoY % growth | -96.648M 36.87% | -85.448M 11.59% | -88.128M -3.14% | -54.548M 38.10% | -41.494M 23.93% | -18.659M 55.03% | -30.704M -64.55% | -9.09M 70.39% | |
| Operating Margin | -16.34% | -12.94% | -12.12% | -6.78% | -4.70% | -1.94% | -2.97% | -0.81% | |
| EPS YoY % growth | -0.11 80.36% | 0.10 190.91% | 0.12 20.00% | 0.17 39.26% | 0.32 90.03% | 0.45 41.16% | 0.63 39.69% | 0.82 30.65% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.01 | 0.04 20.09% | 0.06 91.13% | 0.08 25.61% | 0.05 637.21% | 0.08 112.45% | 0.09 60.49% | 0.11 43.10% | 0.08 39.17% | 0.11 45.16% | 0.15 59.15% | 0.19 77.94% |
| Revenue Q2Q % growth | 186.38M 10.92% | 198.37M 9.40% | 207.86M 10.68% | 212.17M 11.57% | 206.58M 10.84% | 218.02M 9.91% | 226.83M 9.13% | 231.85M 9.28% | 222.3M 7.61% | 241.29M 10.67% | 250.68M 10.51% | 253.81M 9.47% |
| EBITDA Q2Q % growth | 8.77M 186.86% | 12.812M 73.02% | 16.586M -47.35% | 17.513M -68.18% | 14.93M 70.24% | 18.645M 45.53% | 22.116M 33.34% | 22.615M 29.13% | 23.331M 56.27% | 24.24M 30.01% | 25.048M 13.26% | 25.452M 12.54% |
| EBIT Q2Q % growth | -19.012M 31.67% | -14.992M 45.66% | -10.997M 44.82% | -9.185M 28.18% | -10.685M 43.80% | -6.745M 55.01% | -3.782M 65.61% | -2.75M 70.06% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
55.16%
EPS Next 5 Year
46.80%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
9.56%
Revenue Next 5 Year
8.82%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
42.58%
EBIT Next 5 Year
34.35%
NEOGENOMICS INC / NEO Forecast FAQ
Can you provide the upcoming earnings date for NEOGENOMICS INC?
NEOGENOMICS INC (NEO) will report earnings on 2026-04-27, before the market open.
Can you provide the consensus estimates for NEOGENOMICS INC next earnings?
The consensus EPS estimate for the next earnings of NEOGENOMICS INC (NEO) is 0.01 USD and the consensus revenue estimate is 186.38M USD.
What is the expected long term growth rate for NEOGENOMICS INC (NEO)?
The expected long term growth rate for NEOGENOMICS INC (NEO) is 9.56%.